272 related articles for article (PubMed ID: 34108939)
41. Integrative epigenomic and genomic filtering for methylation markers in hepatocellular carcinomas.
Shen J; LeFave C; Sirosh I; Siegel AB; Tycko B; Santella RM
BMC Med Genomics; 2015 Jun; 8():28. PubMed ID: 26059414
[TBL] [Abstract][Full Text] [Related]
42. Pan-cancer analysis of frequent DNA co-methylation patterns reveals consistent epigenetic landscape changes in multiple cancers.
Zhang J; Huang K
BMC Genomics; 2017 Jan; 18(Suppl 1):1045. PubMed ID: 28198667
[TBL] [Abstract][Full Text] [Related]
43. Diagnosis and treatment of lymphomas in the era of epigenetics.
Chebly A; Chouery E; Ropio J; Kourie HR; Beylot-Barry M; Merlio JP; Tomb R; Chevret E
Blood Rev; 2021 Jul; 48():100782. PubMed ID: 33229141
[TBL] [Abstract][Full Text] [Related]
44. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation.
Schatz-Siemers N; Brandler TC; Oweity T; Sun W; Hernandez A; Levine P
Diagn Cytopathol; 2019 Oct; 47(10):977-985. PubMed ID: 31293091
[TBL] [Abstract][Full Text] [Related]
45. Frequent chromosomal DNA unbalance in thyroid oncocytic (Hürthle cell) neoplasms detected by comparative genomic hybridization.
Tallini G; Hsueh A; Liu S; Garcia-Rostan G; Speicher MR; Ward DC
Lab Invest; 1999 May; 79(5):547-55. PubMed ID: 10334566
[TBL] [Abstract][Full Text] [Related]
46. Thyroid Hürthle cell tumors: research of potential markers of malignancy.
Donatini G; Beaulieu A; Castagnet M; Kraimps JL; Levillain P; Fromont G
J Endocrinol Invest; 2016 Feb; 39(2):153-8. PubMed ID: 26188382
[TBL] [Abstract][Full Text] [Related]
47. RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hürthle cell carcinomas?
Musholt PB; Imkamp F; von Wasielewski R; Schmid KW; Musholt TJ
Surgery; 2003 Dec; 134(6):881-9; discussion 889. PubMed ID: 14668719
[TBL] [Abstract][Full Text] [Related]
48. Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment.
Radpour R; Barekati Z; Kohler C; Schumacher MM; Grussenmeyer T; Jenoe P; Hartmann N; Moes S; Letzkus M; Bitzer J; Lefkovits I; Staedtler F; Zhong XY
PLoS One; 2011; 6(11):e27355. PubMed ID: 22076154
[TBL] [Abstract][Full Text] [Related]
49. A Tox21 Approach to Altered Epigenetic Landscapes: Assessing Epigenetic Toxicity Pathways Leading to Altered Gene Expression and Oncogenic Transformation In Vitro.
Parfett CL; Desaulniers D
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587163
[TBL] [Abstract][Full Text] [Related]
50. Integrated analyses of multi-omics reveal global patterns of methylation and hydroxymethylation and screen the tumor suppressive roles of HADHB in colorectal cancer.
Zhu Y; Lu H; Zhang D; Li M; Sun X; Wan L; Yu D; Tian Y; Jin H; Lin A; Gao F; Lai M
Clin Epigenetics; 2018; 10():30. PubMed ID: 29507648
[TBL] [Abstract][Full Text] [Related]
51. Cancer epigenomics: DNA methylomes and histone-modification maps.
Esteller M
Nat Rev Genet; 2007 Apr; 8(4):286-98. PubMed ID: 17339880
[TBL] [Abstract][Full Text] [Related]
52. An immunohistochemical study of thyroid Hurthle cells and their neoplasms: the roles of S-100 and HMB-45 proteins.
Abu-Alfa AK; Straus FH; Montag AG
Mod Pathol; 1994 Jun; 7(5):529-32. PubMed ID: 7937716
[TBL] [Abstract][Full Text] [Related]
53. Investigation of epigenetics in kidney cell biology.
Li LX; Agborbesong E; Zhang L; Li X
Methods Cell Biol; 2019; 153():255-278. PubMed ID: 31395383
[TBL] [Abstract][Full Text] [Related]
54. PVALB, a new Hürthle adenoma diagnostic marker identified through gene expression.
Cerutti JM; Oler G; Delcelo R; Gerardt R; Michaluart P; de Souza SJ; Galante PA; Huang P; Riggins GJ
J Clin Endocrinol Metab; 2011 Jan; 96(1):E151-60. PubMed ID: 20926528
[TBL] [Abstract][Full Text] [Related]
55. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
Oh S; Ko JY; Oh C; Yoo KH
Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
[TBL] [Abstract][Full Text] [Related]
56. Prognostic and Predictive Epigenetic Biomarkers in Oncology.
Kamińska K; Nalejska E; Kubiak M; Wojtysiak J; Żołna Ł; Kowalewski J; Lewandowska MA
Mol Diagn Ther; 2019 Feb; 23(1):83-95. PubMed ID: 30523565
[TBL] [Abstract][Full Text] [Related]
57. MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.
Kasaian K; Chindris AM; Wiseman SM; Mungall KL; Zeng T; Tse K; Schein JE; Rivera M; Necela BM; Kachergus JM; Casler JD; Mungall AJ; Moore RA; Marra MA; Copland JA; Thompson EA; Smallridge RC; Jones SJ
J Clin Endocrinol Metab; 2015 Apr; 100(4):E611-5. PubMed ID: 25625803
[TBL] [Abstract][Full Text] [Related]
58. Chromosomal aberrations by comparative genomic hybridization in hürthle cell thyroid carcinomas are associated with tumor recurrence.
Wada N; Duh QY; Miura D; Brunaud L; Wong MG; Clark OH
J Clin Endocrinol Metab; 2002 Oct; 87(10):4595-601. PubMed ID: 12364440
[TBL] [Abstract][Full Text] [Related]
59. Molecular Characterization of an Endometrial Endometrioid Adenocarcinoma Metastatic to a Thyroid Hürthle Cell Adenoma Showing Cancerization of Follicles.
Afrogheh AH; Meserve E; Sadow PM; Stephen AE; Nosé V; Berlin S; Faquin WC
Endocr Pathol; 2016 Sep; 27(3):213-9. PubMed ID: 26687112
[TBL] [Abstract][Full Text] [Related]
60. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions.
Chiappetta G; Toti P; Cetta F; Giuliano A; Pentimalli F; Amendola I; Lazzi S; Monaco M; Mazzuchelli L; Tosi P; Santoro M; Fusco A
J Clin Endocrinol Metab; 2002 Jan; 87(1):364-9. PubMed ID: 11788677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
